Drug Trial Radar · NCT00796263
Antiretroviral Therapy for Acute and Chronic HIV Infection
Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
May 13, 2009
Primary completion
Jun 2033
Study completion Jun 2033
Sponsor
- Lead sponsor
- SEARCH Research FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ViiV Healthcare
- First posted
- Nov 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose for this protocol is to provide safe and effective standard ART to SEARCH 010 and SEARCH 013 participants. Participants are enrolled in an acute HIV infection study (SEARCH 010 protocol: 'Establish and characterize an acute HIV infection cohort in a Thai high-risk population') or in a study of chronic HIV infection (SEARCH 013 protocol 'Characteristics of immunity in gut mucosa, spinal fluid, lymph node and blood of HIV negative and HIV positive Thais').
Conditions
- Acute HIV Infection
- Chronic HIV Infection
Interventions
HAARTDrug
1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily plus dolutegravir(DTG) 50 mg orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- HIV-related clinical eventsTime frame: 10 years
- Immunologic parameters including CD4 count and CD4/CD8 ratioTime frame: 10 years
- Virologic parameters including HIV RNA and HIV reservoir markersTime frame: 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of HIV Research and Innovation
Bangkok, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.